ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CTLA-4 Monoclonal Antibody SHR-8068

Also written as “SHR-8068 Injection”, “SHR-8068” and “SHR-8068 + Adebrelimab + Bevacizumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Colorectal Neoplasms · Carcinoma, Renal Cell · Rectal Neoplasms, led by Jiangsu HengRui Medicine.

Drug pageAnti-CTLA-4 Monoclonal Antibody SHR-8068: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 21, 202416 company-led studies, 15 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine1615 open or runningphase 3since Mar 21, 2024May 27, 2022Jul 2027phase 2 · NCT07682272

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since May 27, 2022.

  1. Mar 21, 2024Phase 3 study in Non-squamous Non-small Cell Lung CancerNCT06335355 · 401 planned · China
  2. May 23, 2024Phase 2 study in Advanced Non-small Cell Lung CancerNCT06434103
  3. Sep 6, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06589778 · 124 planned · China
  4. Sep 26, 2024Phase 3 study in Advanced Hepatocellular CarcinomaNCT06618664 · 590 planned · China
  5. Jul 8, 20252 phase 2 studiesNCT07071714, NCT07110571
  6. Sep 5, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07170995 · 460 planned · China
  7. Nov 13, 2025Phase 3 study in Advanced Biliary Tract CancerNCT07229625 · 604 planned · China
  8. Nov 14, 20252 phase 2 studiesNCT07241767, NCT07239596
  9. Feb 25, 2026Phase 3 study in Locally Advanced Resectable Rectal CancerNCT07454720 · 165 planned · China
  10. Jun 26, 2026Phase 2 study in Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskNCT07682272 · 120 planned · China
  11. Jul 2, 2026Phase 3 study in Carcinoma, HepatocellularNCT07691762 · 690 planned · China
  12. Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645 · 180 planned · China
  13. Sep 25, 2026Primary completion moved from 2026-09 to 2026-10Date moved laterphase 3 · +1 months · NCT06618664
  14. Oct 29, 2026Primary completion moved from 2031-04 to 2031-09Date moved laterphase 3 · +5 months · NCT07691762

Ahead

  1. Jul 2027Primary completion: phase 2 study in Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskNCT07682272
  2. Nov 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07241767
  3. Jun 2028Primary completion: phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645
  4. Oct 2028Primary completion: phase 3 study in Non-squamous Non-small Cell Lung CancerNCT06335355

TargetBeta

CTLA4 →read by rule
“A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4; CTLA4; CD152), ”NCIt, by rule

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
tremelimumabruleAstraZenecaphase 347
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
erfonrilimabruleAlphamab Oncologyphase 314
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologicsphase 311
gotistobartruleoncoc4-incphase 35
zalifrelimabruleAgenusphase 26
porustobartruleharbour-biomed-guangzhou-co-ltdphase 25
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
GB268ruleeddingpharm-zhuhai-co-ltdphase 22

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07704645Resectable Non-small Cell Lung Cancer · China2Not yet recruitingJun 2028180
NCT07691762Carcinoma, Hepatocellular · China3Not yet recruitingSep 2031690
NCT07682272Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk · China2Not yet recruitingJul 2027120
NCT07454720Locally Advanced Resectable Rectal Cancer · China3RecruitingNov 2032165
NCT07239596Advanced Renal Cell Carcinoma · China2RecruitingDec 203092
NCT07241767Lung Neoplasms · China2RecruitingNov 2027200
NCT07229625Advanced Biliary Tract Cancer · China3RecruitingDec 2029604
NCT07170995Carcinoma, Non-Small-Cell Lung · China3RecruitingDec 2030460
NCT07110571Stomach Neoplasms · China2RecruitingAug 2026200
NCT07071714Colorectal Neoplasms · China2Active, not recruitingOct 2031103
NCT06618664Advanced Hepatocellular Carcinoma · China3RecruitingOct 2026590
NCT06589778Carcinoma, Non-Small-Cell Lung · China2RecruitingApr 30, 2026124
NCT06434103Advanced Non-small Cell Lung Cancer2WithdrawnOct 10, 20240
NCT06335355Non-squamous Non-small Cell Lung Cancer · China3Not yet recruitingOct 2028401
NCT06247956Esophageal Squamous Cell Carcinoma · China2Active, not recruitingDec 30, 2025153
NCT05416775Advanced Non-small Cell Lung Cancer · China2RecruitingJun 30, 2026168

How it is read

Names in the registry

  • “SHR-8068 Injection”, 4 entries
  • “SHR-8068”, 2 entries
  • “SHR-8068 + Adebrelimab + Bevacizumab”, 1 entry
  • “SHR-8068;Adebrelimab ;Bevacizumab”, 1 entry
  • “SHR-8068 ; SHR-4610”, 1 entry

Codes read as this program: SHR8068.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.